LIVE POLIO IRUS VACCINES

624 Index
pH neutralization test, 68, 208, 243, 330, 489, 531
compared with CPE method, 121, 228, 268
for low avidity antibody determination, 228, 384
Pharyngeal infection
and conversion response, 350
and maternal antibody influence, 327
and spread by contact, 188
dose relationship, 296
immunologic resistance of cells, 414
in monkeys, effect of immune milk, 325
isolation of virus, 144, 203, 341-354, 357-364
related to vaccine form, 357
Pharyngeal surgery
and polio risk, 461, 597
Pharyngeal swabs
technique, 294, 315, 359
Philadelphia
field trial, 277-283, 598
Philippines
longitudinal study of polio, 203
Phosphate buffer
elution marker study, 42
Phosphorus, radioactive (P3 2 )
poliovirus grown in presence of, 41
Photodynamic action of dyes
differential destruction of B virus, 87
Physical properties
as a "views" marker, 41-43
"Ping-pong" effect
exchange of viruses between susceptibles, 113
Placebo studies
food handlers, 357
in evaluation of live virus vaccine, 157
not indicated or practicable, 445, 463
Plaque technique, 68, 125, 469, 580
count assay
differences between days, 66
differences between laboratories, 122
discrepancies, pH and CP tests, 268
on vaccine candy, 425
screen for neurovirulence, 125
decrease in number by homologous strain, 53-54
in deuterated medium with CHAT, 62-64
in reproductive capacity temperature study, 103
lines and temperature variation, 109
number (PFU) inoculated IM, 92
selection of single virus particle progeny, 5
to original fecal suspension, 203, 205
Plotkin, Stanley A., paper 53-65, 277-283, 287-293,
294-301, 466-473; 7, 54, 123, 144, 214, 324-
326, 371-372, 377, 465, 480-481, 532
Plzen, Czechoslovakia
Salk program, 507, 513
Podsedlovsky, T. S., paper 413-428
Poland
field trial, 522-531
map, 528-529
Type 1 isolate, 1st results, 55
Poland organizations
Ministry of Health, 522
Provincial Public Health Laboratories, Lublin, 522,
526
State Institute of Hygiene, Warsaw, 522, 527
Poliomyelitis, see also Incidence, Morbidity, Mortality,
Poliomyelitis paralytic, Poliomyelitis
virus, etc.
age and economic status, 158
age and infection, rate, 378
age distribution, Costa Rica, 561
antibody titer differences, reasons, 235
attack rates,
high, virulent virus selection, 575
low in control groups, 505
low in vaccinated areas, 603
cases, 410, 453, 455-456, 458, 469, 569-570, 575
frequency within normal limits in vaccination,
473
high ratio of paralytic, 457
interval between vaccination and onset, 398
none before trial, 537
not induced by vaccine, 601
not serologically confirmed, 458
case reporting, 464, 486
criteria for designating a vaccine-associated case,
457
diagnosis, 487
dissemination, 411
eradication problem, 158, 518, 577, 603
increasing importance, 561
incidence,
and vaccine safety, 4
Baltic republics, 577
by age and sex, 191
chain of transmission, 594
Cincinnati, 591-592
Czechoslovakia, map, 517
Dade County, Florida, 448, 459
major outbreaks every two years, 386
Mauritius, 476
Minnesota, 376
Netherlands, 134, 137, 143
Nicaragua, 575
non-vaccinated children, 401
Philadelphia, 277
U.S.A., 158, 337
USSR, 430
vaccinated and nonvaccinated, 401, 411
prophylaxis, 413
reinfection prevention in vaccinated communities,
410
resistance in convalescents, 262
simultaneous entrance of vaccine and wild virus.
157, 182
spread pattern, 171, 202
spread reduction, 410-411, 576
susceptibility
in Salk vaccinees, 576
reduction to adult level, 367, 368
type specific, 559
vaccine influence, 377
Poliomyelitis, paralytic
attack rates, Florida, 446
among vaccinees,
appreciable drop, 429
clinical histories, 402-409, 557-558
14 of 59 confirmed cases, 571